Total income for the quarter rose 14.24 per cent YoY to Rs 1,997 crore compared with Rs 1,748 crore in the corresponding last year. The company continued to have near normal operations during the quarter complying to all Covid-19 protocols, the company said in a BSE filing.
The numbers were boosted by forex gains of Rs 20 crore against Rs 5 crore gain in the corresponding quarter last year.
Profit before tax (PBT) for the quarter came in at Rs 814 crore against Rs 661 crore in the year-ago quarter.
On a standalone basis, PAT came in at Rs 552 crore against Rs 492 crore YoY. Total revenue was up at Rs 1,986 crore compared with Rs 1,728 crore YoY.
The company is engaged in the manufacture of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients. The scrip closed at Rs 4,915.90 on BSE, down 0.15 per cent.
